Breakthrough in Lung Cancer Treatment: Ivonescimab Shows Promise

An experimental drug, ivonescimab, by Akeso has prolonged the life of lung cancer patients by 15% compared to Tevimbra, reducing mortality risk by over a third. Introduced as a first-line treatment alongside chemotherapy, the drug showcases its potential as a new standard of care for squamous non-small cell lung cancer.

An experimental drug developed by the China-based company Akeso has demonstrated significant promise in treating advanced squamous non-small cell lung cancer. This treatment, known as ivonescimab, extended patient lifespans by 15% compared to BeOne Medicines' immunotherapy, Tevimbra, while reducing the risk of death by more than a third, as per recent study findings.

Conducted in China, the head-to-head study included 532 patients with advanced-stage lung cancer, comparing the effects of ivonescimab and Tevimbra when combined with chemotherapy. Preliminary results appear encouraging, yet the applicability of these findings outside China remains unclear due to potential ethnic response variations, said Dr. David Spigel of the Sarah Cannon Research Institute.

Ivonescimab, categorized as a bispecific antibody, targets both the PD-1 protein and VEGF, potentially positioning it as a new standard of care if further global trials reaffirm its effectiveness. Although a U.S. approval is not currently feasible, continued global trials could pave the way for international regulatory submissions.